The finding that human epidermal growth factor receptor 2 (HER2) overexpression may be implicated in the development of gastric cancer has led to exciting new investigations into the role of anti-HER2 therapy in combating this disease.
Herceptin is approved in the EU for patients with HER2-positive advanced stomach cancer
More Information
HER2 is overexpressed in around 20% of all gastric cancer cases, suggesting that Herceptin (trastuzumab) could potentially be used to suppress tumour growth.
The accurate identification of HER2-positive gastric tumours is essential for determining potential eligibility for the ToGA trial.
Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer
More Information
Herceptin is approved for the treatment of women with early and metastatic HER2-positive breast cancer and patients with HER2-positive metastatic gastric cancer.